Mach7 (ASX:M7T) ARR has declined slightly and Mach7 missed its operating cash flow guidance in Q4 FY 2023. However, Q1 FY 2024 should be stronger.

Mach7 Technologies (ASX: M7T) reported record sales but relatively weak cash flow in Q2 FY 2023.

Mach7 Technologies has announced its biggest ever contract win with Akumin, but its lack of profitability and CFO departure weigh on the mind.

These two med-tech stocks are still fairly high risk, but they are approaching the profitability inflection point, and have long term tailwinds supporting the businesses.

Some stocks have high multiples and higher growth rates, others have lower multiples and lower growth rates. Here’s how I decided which one to choose.

8Common (ASX: 8CO) and Mach7 Technologies (ASX: M7T) are two small Aussie software stocks with strong share price momentum.